MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy.
Recent studies in human and murine systems suggest a central role for CD4+ T cells in initiating, effecting and maintaining anti-tumor immunity. Characterization of the tumor-associated antigens recognized by CD4+ T cells may prove critical to the success of cancer immunotherapy strategies.
Topalian
S L
SL
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D006681:HLA-D Antigens / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D007156:Immunologic Memory; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
D000951:Antigens, Neoplasm; D006681:HLA-D Antigens; D000949:Histocompatibility Antigens Class II